Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

ClinicalTrials.gov ID: NCT00343785

Public ClinicalTrials.gov record NCT00343785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial

Study identification

NCT ID
NCT00343785
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
21 participants

Conditions and interventions

Interventions

  • cyclophosphamide Drug
  • anti-thymocyte globulin Biological
  • cyclosporine Drug
  • allogeneic bone marrow transplantation Procedure
  • methotrexate Drug
  • DNA analysis Genetic
  • flow cytometry Other
  • polymorphism analysis Genetic
  • laboratory biomarker analysis Other

Drug · Biological · Procedure + 2 more

Eligibility (public fields only)

Age range
Up to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Apr 30, 2012
Completion
Jul 31, 2012
Last update posted
Apr 12, 2017

2006 – 2012

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle Washington 98109
Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00343785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00343785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →